RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020

Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions...

Descripción completa

Detalles Bibliográficos
Autores principales: Packnett, Elizabeth R., Winer, Isabelle H., Larkin, Heather, Oladapo, Abiola, Gonzales, Tara, Wojdyla, Matthew, Goldstein, Mitchell, Smith, Vincent C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Immunotherapeutics – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746385/
https://www.ncbi.nlm.nih.gov/pubmed/36412253
http://dx.doi.org/10.1080/21645515.2022.2140533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746385/
https://www.ncbi.nlm.nih.gov/pubmed/36412253
http://dx.doi.org/10.1080/21645515.2022.2140533

Ejemplares similares